Objective To investigate the clinical significance of phosphorylated caspase-8 by Src in patients with operable non-small cell lung cancer. Methods Src and caspase-8 expressions were tested using immunohistochemistry in non-small cell lung cancer tissues and control lung tissues. The expression of phosphorylated caspase-8 at 380 tyrosine by Src was detected using Western blotting. The disease-free survival (DFS) of patients positive and negative for phosphorylated caspase-8 was analyzed with Kaplan-Meire survival curve. Results No significant difference was found in the positivity rate of caspase-8 or Src between the cancer tissues and control lung tissues (76.3% vs 83.3%, P>0.05; 70.1% vs 66.4%, P>0.05). All the patients with Casp8-and Src-positive cancers were positive for phosphoryalted caspase-8, whose expression rate was significantly higher in the cancer tissues than in the paired control lung tissues (52.4%vs 7.1%, P<0.05). The 2-year DFS was significantly higher in patients negative for phosphorylated caspase- 8 than in the positive patients (32.0% vs 60.3% , P<0.05). Conclusion Phosphorylated caspase-8 may serve as a predictor for a poorer DFS in patients with operable non-small cell lung cancer.%目的：探索Src对caspase-8的磷酸化作用对非小细胞肺癌患者的临床意义。方法应用免疫组化方法检测Src及caspase-8在非小细胞肺癌组织及对照肺组织中的表达，应用Western blot检测非小细胞肺癌组织和对照肺组织的磷酸化caspase-8（p-Y380-casp8）的表达，Kaplan-Meire法分析p-Y380-casp8阳性组和阴性组的无疾病生存情况。结果 Caspase-8与Src在非小细胞肺癌组织和对照肺组织中阳性表达率无显著性差异（P>0.05），免疫组化caspase-8（+）Src（+）的非小细胞肺癌组织中磷酸化caspase-8均阳性表达，磷酸化caspase-8在非小细胞肺癌组织中的阳性率显著高于对照肺组织（52.4%vs 7.1%，P<0.05），磷酸化caspase-8阳性表达非小细胞肺癌患者组术后2年无疾病生存率显著低于磷酸化caspase-8阴性组（32.0%vs 60.3%，P<0.05）。结论磷酸化caspase-8可以成为非小细胞肺癌患者不佳预后的标志分子，为临床非小细胞肺癌患者预后评估提供了全新理论基础。
展开▼
